Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Jul, 2017 | Pages:
80 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Pipeline Review, H2 2017 Summary Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) pipeline Target constitutes close to 21 molecules. Out of which approximately 14 molecules are developed by companies and remaining by the universities/institutes. The latest report Mucin 1 - Pipeline Review, H2 2017, outlays comprehensive information on the Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Mucin 1, cell surface associated (MUC1) or polymorphic epithelial mucin (PEM) is a mucin encoded by the MUC1 gene. It acts both as an adhesion and an anti-adhesion protein. It provides a protective layer on epithelial cells against bacterial and enzyme attack. It is involved in cell signaling through phosphorylations and protein-protein interactions. It modulates signaling in ERK, SRC and NF-kappa-B pathways. It promotes tumor progression. It regulates TP53-mediated transcription and determines cell fate in the genotoxic stress response. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 1, 6 and 1 respectively. Similarly, the universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 5 and 1 molecules, respectively. Report covers products from therapy areas Oncology and Non Malignant Disorders which include indications Breast Cancer, Prostate Cancer, Non-Small Cell Lung Cancer, Colon Cancer, Lung Cancer, Ovarian Cancer, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Adenocarcinoma, Adenomas, Colorectal Cancer, Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Multiple Myeloma (Kahler Disease), Non Muscle Invasive Bladder Cancer (NMIBC) (Superficial Bladder Cancer), Refractory Acute Myeloid Leukemia, Relapsed Acute Myeloid Leukemia and Solid Tumor. Furthermore, this report also reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - The report reviews Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics and enlists all their major and minor projects - The report assesses Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news and deals related to Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) targeted therapeutics Reasons to buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand the targeted therapy areas and indications for Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Identify the use of drugs for target identification and drug repurposing - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) development landscape - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
List of Tables List of Figures Introduction Global Markets Direct Report Coverage Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Overview Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Therapeutics Development Products under Development by Stage of Development Products under Development by Therapy Area Products under Development by Indication Products under Development by Companies Products under Development by Universities/Institutes Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Therapeutics Assessment Assessment by Mechanism of Action Assessment by Route of Administration Assessment by Molecule Type Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Companies Involved in Therapeutics Development Akshaya Bio Inc Bavarian Nordic A/S Boehringer Ingelheim GmbH Etubics Corp GeoVax Labs Inc Merck KGaA Minerva Biotechnologies Corp Transgene SA Vaxil Bio Therapeutics Ltd Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Drug Profiles BI-1361849 - Drug Profile Product Description Mechanism Of Action R&D Progress Cellular Immunotherapy to Target MUC1 for Gastric Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress CV-301 - Drug Profile Product Description Mechanism Of Action R&D Progress GO-203/NPs - Drug Profile Product Description Mechanism Of Action R&D Progress GO-2032c - Drug Profile Product Description Mechanism Of Action R&D Progress ImMucin - Drug Profile Product Description Mechanism Of Action R&D Progress Monoclonal Antibody to Inhibit MUC1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress tecemotide - Drug Profile Product Description Mechanism Of Action R&D Progress TG-4010 - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine 1 to Target MUC-1 Protein for Breast Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine 2 to Target MUC-1 for Breast Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine 3 to Target MUC-1 Protein for Breast Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target MUC-1 and TLR-2 for Breast Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target MUC-1 for Cancer - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target MUC1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target MUC1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target MUC1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target MUC1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target MUC1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Vaccine to Target Mucin 1 for Oncology - Drug Profile Product Description Mechanism Of Action R&D Progress Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Dormant Products Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Discontinued Products Mucin 1 (Breast Carcinoma Associated Antigen DF3 or Episialin or H23AG or Krebs Von Den Lungen 6 or PEMT or Peanut Reactive Urinary Mucin or Polymorphic Epithelial Mucin or Tumor Associated Epithelial Membrane Antigen or Tumor Associated Mucin or CD227 or MUC1) - Product Development Milestones Featured News & Press Releases May 23, 2017: Vaxil Launches Manufacturing of ImMucin Immunotherapy for Upcoming Clinical Trials Mar 21, 2017: Direct Tumor Vaccination Shown to Induce Anti-tumor Immunity and Increase Survival in a Murine Model of Pancreatic Cancer Mar 13, 2017: First Patient Dosed in Phase 2 Trial Evaluating Transgenes TG4010 in Combination With Opdivo (Nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer Mar 10, 2017: Bavarian Nordic Announces Collaboration to Evaluate CV301 and Tecentriq in Bladder Cancer Mar 03, 2017: Vaxil Announces Novel Immunotherapy Poster Presentation at 2017 American Association for Cancer Research Meeting Jan 04, 2017: Bristol-Myers, Bavarian Nordic test Opdivo-plus-vaccine combo in lung cancer Dec 29, 2016: Bavarian Nordic Initiates Trial of CV301 in Combination with Nivolumab in Patients with Lung Cancer Dec 07, 2016: UC Davis to Conduct Phase 2 Trial of the Combination of TG4010 with Opdivo (nivolumab) for 2nd Line Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC) Nov 29, 2016: Vaxil Reports Preliminary Data From Checkpoint Inhibitors in Combination With Immucin Aug 15, 2016: Bavarian Nordic Announces Drug Supply Agreement with Bristol-Myers Squibb for NSCLC Clinical Study Aug 04, 2016: Vaxil Announces Key US Patent and Trademark Office Notice of Allowance for Its Immunotherapy Jun 16, 2016: Vaxil Receives Positive Response From European Patent Office for the Allowance of the Immunotherapy Orphan Drug Designated ImMucin Apr 20, 2016: Studies published in "Oncogene" demonstrate that MUC1-C regulates DNA methylation in human carcinoma cells Mar 31, 2016: Vaxil Receives Canadian Notice of Patent Allowance for Its Lead Immunotherapy Platform, Including Its ImMucin Cancer Vaccine Mar 16, 2016: Genus Oncology completes enrollment to Phase 1b dose escalation study of GO-203 for the treatment of relapsed/refractory AML Appendix Methodology Coverage Secondary Research Primary Research Expert Panel Validation Contact Us Disclaimer
List of Tables
Number of Products under Development by Stage of Development, H2 2017 Number of Products under Development by Therapy Areas, H2 2017 Number of Products under Development by Indication, H2 2017 Number of Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 Products under Development by Companies, H2 2017 (Contd..1), H2 2017 Number of Products under Investigation by Universities/Institutes, H2 2017 Products under Investigation by Universities/Institutes, H2 2017 Number of Products by Stage and Mechanism of Actions, H2 2017 Number of Products by Stage and Route of Administration, H2 2017 Number of Products by Stage and Molecule Type, H2 2017 Pipeline by Akshaya Bio Inc, H2 2017 Pipeline by Bavarian Nordic A/S, H2 2017 Pipeline by Boehringer Ingelheim GmbH, H2 2017 Pipeline by Etubics Corp, H2 2017 Pipeline by GeoVax Labs Inc, H2 2017 Pipeline by Merck KGaA, H2 2017 Pipeline by Minerva Biotechnologies Corp, H2 2017 Pipeline by Transgene SA, H2 2017 Pipeline by Vaxil Bio Therapeutics Ltd, H2 2017 Dormant Products, H2 2017 Dormant Products, H2 2017 (Contd..1), H2 2017 Discontinued Products, H2 2017
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
